Table of Content

1. Report Introduction

2. Onychomycosis Market Overview at a Glance
2.1. Market Share Distribution of Onychomycosis in 2018
2.2. Market Share Distribution of Onychomycosis in 2028

3. Disease Background and Overview: Onychomycosis
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Onychomycosis in 7MM
4.3. Total Prevalent Patient Population of Onychomycosis in 7MM – By Countries

5. Epidemiology of Onychomycosis by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Onychomycosis
5.1.3. Sub-Type Specific cases of the Onychomycosis *Indication Specific
5.1.4. Sex- Specific Cases of the Onychomycosis*Indication Specific
5.1.5. Diagnosed Cases of the Onychomycosis
5.1.6. Treatable Cases of the Onychomycosis
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Onychomycosis
5.4.3. Sub-Type Specific cases of the Onychomycosis*

5.4.4. Sex- Specific Cases of the Onychomycosis*

5.4.5. Diagnosed Cases of the Onychomycosis
5.4.6. Treatable Cases of the Onychomycosis
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Onychomycosis
5.5.3. Sub-Type Specific cases of the Onychomycosis*

5.5.4. Sex- Specific Cases of the Onychomycosis*

5.5.5. Diagnosed Cases of the Onychomycosis
5.5.6. Treatable Cases of the Onychomycosis
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Onychomycosis
5.6.3. Sub-Type Specific cases of the Onychomycosis*

5.6.4. Sex- Specific Cases of the Onychomycosis*

5.6.5. Diagnosed Cases of the Onychomycosis
5.6.6. Treatable Cases of the Onychomycosis
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Onychomycosis
5.7.3. Sub-Type Specific cases of the Onychomycosis*

5.7.4. Sex- Specific Cases of the Onychomycosis*

5.7.5. Diagnosed Cases of the Onychomycosis
5.7.6. Treatable Cases of the Onychomycosis
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Onychomycosis
5.8.3. Sub-Type Specific cases of the Onychomycosis*

5.8.4. Sex- Specific Cases of the Onychomycosis*

5.8.5. Diagnosed Cases of the Onychomycosis
5.8.6. Treatable Cases of the Onychomycosis
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Onychomycosis
5.9.3. Sub-Type Specific cases of the Onychomycosis*

5.9.4. Sex- Specific Cases of the Onychomycosis*

5.9.5. Diagnosed Cases of the Onychomycosis
5.9.6. Treatable Cases of the Onychomycosis

6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines

7. Unmet Needs of the Onychomycosis

8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile

9. Pipeline Therapies – At a glance

10. Key Cross Competition

11. Emerging Therapies for Onychomycosis
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile

12. Onychomycosis: 7MM Market Analysis
12.1. 7MM Market Size of Onychomycosis
12.2. 7MM Percentage Share of drugs marketed for Onychomycosis
12.3. 7MM Market Sales of Onychomycosis by Products

13. Onychomycosis: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Onychomycosis in United States
13.1.2. Percentage Share of drugs marketed for Onychomycosis in United States
13.1.3. Market Sales of Onychomycosis by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Onychomycosis in Germany
13.2.1.2. Percentage Share of drugs marketed for Onychomycosis in Germany
13.2.1.3. Market Sales of Onychomycosis by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Onychomycosis in France
13.2.2.2. Percentage Share of drugs marketed for Onychomycosis in France
13.2.2.3. Market Sales of Onychomycosis by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Onychomycosis in Italy
13.2.3.2. Percentage Share of drugs marketed for Onychomycosis in Italy
13.2.3.3. Market Sales of Onychomycosis by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Onychomycosis in Spain
13.2.4.2. Percentage Share of drugs marketed for Onychomycosis in Spain
13.2.4.3. Market Sales of Onychomycosis by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Onychomycosis in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Onychomycosis in United Kingdom
13.2.5.3. Market Sales of Onychomycosis by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Onychomycosis in Japan
13.3.2. Percentage Share of drugs marketed for Onychomycosis in Japan
13.3.3. Market Sales of Onychomycosis by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

14. Market Drivers

15. Market Barriers

16. Appendix

17. Report Methodology
17.1. Sources

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight



List of Figures


Figure 1: Total Prevalent/Incident Cases of the Onychomycosis in 7MM
Figure 2: Total Prevalent/Incident Cases of the Onychomycosis in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Onychomycosis in United States (2017-2028)
Figure 4: Sub-Type Specific cases of the Onychomycosis in United States (2017-2028)
Figure 5: Sex- Specific Cases of the Onychomycosis in United States (2017-2028)
Figure 6: Diagnosed Cases of the Onychomycosis in United States (2017-2028)
Figure 7: Treatable Cases of the Onychomycosis in United States (2017-2028)
Figure 8: Prevalent/Incident Cases of the Onychomycosis in Germany (2017-2028)
Figure 9: Sub-Type Specific cases of the Onychomycosis in Germany (2017-2028)
Figure 10: Sex- Specific Cases of the Onychomycosis in Germany (2017-2028)
Figure 11: Diagnosed Cases of the Onychomycosis in Germany (2017-2028)
Figure 12: Treatable Cases of the Onychomycosis in Germany (2017-2028)
Figure 13: Prevalent/Incident Cases of the Onychomycosis in France (2017-2028)
Figure 14: Sub-Type Specific cases of the Onychomycosis in France (2017-2028)
Figure 15: Sex- Specific Cases of the Onychomycosis in France (2017-2028)
Figure 16: Diagnosed Cases of the Onychomycosis in France (2017-2028)
Figure 17: Treatable Cases of the Onychomycosis in France (2017-2028)
Figure 18: Prevalent/Incident Cases of the Onychomycosis in Italy (2017-2028)
Figure 19: Sub-Type Specific cases of the Onychomycosis in Italy (2017-2028)
Figure 20: Sex- Specific Cases of the Onychomycosis in Italy (2017-2028)
Figure 21: Diagnosed Cases of the Onychomycosis in Italy (2017-2028)
Figure 22: Treatable Cases of the Onychomycosis in Italy (2017-2028)
Figure 23: Prevalent/Incident Cases of the Onychomycosis in Spain (2017-2028)
Figure 24: Sub-Type Specific cases of the Onychomycosis in Spain (2017-2028)
Figure 25: Sex- Specific Cases of the Onychomycosis in Spain (2017-2028)
Figure 26: Diagnosed Cases of the Onychomycosis in Spain (2017-2028)
Figure 27: Treatable Cases of the Onychomycosis in Spain (2017-2028)
Figure 28: Prevalent/Incident Cases of the Onychomycosis in UK (2017-2028)
Figure 29: Sub-Type Specific cases of the Onychomycosis in UK (2017-2028)
Figure 30: Sex- Specific Cases of the Onychomycosis in UK (2017-2028)
Figure 31: Diagnosed Cases of the Onychomycosis in UK (2017-2028)
Figure 32: Treatable Cases of the Onychomycosis in UK (2017-2028)
Figure 33: Prevalent/Incident Cases of the Onychomycosis in Japan (2017-2028)
Figure 34: Sub-Type Specific cases of the Onychomycosis in Japan (2017-2028)
Figure 35: Sex- Specific Cases of the Onychomycosis in Japan (2017-2028)
Figure 36: Diagnosed Cases of the Onychomycosis in Japan (2017-2028)
Figure 37: Treatable Cases of the Onychomycosis in Japan (2017-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Onychomycosis in USD MM (2017-2028)
Figure 42:7MM- Market Share Onychomycosis by Therapies in USD MM (2017-2028)
Figure 43:7MM- Market Sales of Onychomycosis by Therapies in USD MM (2017-2028)
Figure 44: United States-Market Size of Onychomycosis in USD MM (2017-2028)
Figure 45: United States-Market Share Onychomycosis by Therapies in USD MM (2017-2028)
Figure 46: United States-Market Sales of Onychomycosis by Therapies in USD MM (2017-2028)
Figure 47: Germany-Market Size of Onychomycosis in USD MM (2017-2028)
Figure 48: Germany-Market Share Onychomycosis by Therapies in USD MM (2017-2028)
Figure 49: Germany-Market Sales of Onychomycosis by Therapies in USD MM (2017-2028)
Figure 50: France-Market Size of Onychomycosis in USD MM (2017-2028)
Figure 51: France-Market Share Onychomycosis by Therapies in USD MM (2017-2028)
Figure 52: France-Market Sales of Onychomycosis by Therapies in USD MM (2017-2028)
Figure 53: Italy-Market Size of Onychomycosis in USD MM (2017-2028)
Figure 54: Italy-Market Share Onychomycosis by Therapies in USD MM (2017-2028)
Figure 55: Italy-Market Sales of Onychomycosis by Therapies in USD MM (2017-2028)
Figure 56: Spain-Market Size of Onychomycosis in USD MM (2017-2028)
Figure 57: Spain-Market Share Onychomycosis by Therapies in USD MM (2017-2028)
Figure 58: Spain-Market Sales of Onychomycosis by Therapies in USD MM (2017-2028)
Figure 59:UK-Market Size of Onychomycosis in USD MM (2017-2028)
Figure 60:UK-Market Share Onychomycosis by Therapies in USD MM (2017-2028)
Figure 61:UK-Market Sales of Onychomycosis by Therapies in USD MM (2017-2028)
Figure 62: Japan-Market Size of Onychomycosis in USD MM (2017-2028)
Figure 63: Japan-Market Share Onychomycosis by Therapies in USD MM (2017-2028)
Figure 64: Japan-Market Sales of Onychomycosis by Therapies in USD MM (2017-2028)


List of Tables


Table 1: Total Prevalent/Incident Cases of the Onychomycosis in 7MM
Table 2: Total Prevalent/Incident Cases of the Onychomycosis in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Onychomycosis in United States (2017-2028)
Table 4: Sub-Type Specific cases of the Onychomycosis in United States (2017-2028)
Table 5: Sex- Specific Cases of the Onychomycosis in United States (2017-2028)
Table 6: Diagnosed Cases of the Onychomycosis in United States (2017-2028)
Table 7: Treatable Cases of the Onychomycosis in United States (2017-2028)
Table 8: Prevalent/Incident Cases of the Onychomycosis in Germany (2017-2028)
Table 9: Sub-Type Specific cases of the Onychomycosis in Germany (2017-2028)
Table 10: Sex- Specific Cases of the Onychomycosis in Germany (2017-2028)
Table 11: Diagnosed Cases of the Onychomycosis in Germany (2017-2028)
Table 12: Treatable Cases of the Onychomycosis in Germany (2017-2028)
Table 13: Prevalent/Incident Cases of the Onychomycosis in France (2017-2028)
Table 14: Sub-Type Specific cases of the Onychomycosis in France (2017-2028)
Table 15: Sex- Specific Cases of the Onychomycosis in France (2017-2028)
Table 16: Diagnosed Cases of the Onychomycosis in France (2017-2028)
Table 17: Treatable Cases of the Onychomycosis in France (2017-2028)
Table 18: Prevalent/Incident Cases of the Onychomycosis in Italy (2017-2028)
Table 19: Sub-Type Specific cases of the Onychomycosis in Italy (2017-2028)
Table 20: Sex- Specific Cases of the Onychomycosis in Italy (2017-2028)
Table 21: Diagnosed Cases of the Onychomycosis in Italy (2017-2028)
Table 22: Treatable Cases of the Onychomycosis in Italy (2017-2028)
Table 23: Prevalent/Incident Cases of the Onychomycosis in Spain (2017-2028)
Table 24: Sub-Type Specific cases of the Onychomycosis in Spain (2017-2028)
Table 25: Sex- Specific Cases of the Onychomycosis in Spain (2017-2028)
Table 26: Diagnosed Cases of the Onychomycosis in Spain (2017-2028)
Table 27: Treatable Cases of the Onychomycosis in Spain (2017-2028)
Table 28: Prevalent/Incident Cases of the Onychomycosis in UK (2017-2028)
Table 29: Sub-Type Specific cases of the Onychomycosis in UK (2017-2028)
Table 30: Sex- Specific Cases of the Onychomycosis in UK (2017-2028)
Table 31: Diagnosed Cases of the Onychomycosis in UK (2017-2028)
Table 32: Treatable Cases of the Onychomycosis in UK (2017-2028)
Table 33: Prevalent/Incident Cases of the Onychomycosis in Japan (2017-2028)
Table 34: Sub-Type Specific cases of the Onychomycosis in Japan (2017-2028)
Table 35: Sex- Specific Cases of the Onychomycosis in Japan (2017-2028)
Table 36: Diagnosed Cases of the Onychomycosis in Japan (2017-2028)
Table 37: Treatable Cases of the Onychomycosis in Japan (2017-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Onychomycosis in USD MM (2017-2028)
Table 42:7MM- Market Share Onychomycosis by Therapies in USD MM (2017-2028)
Table 43:7MM- Market Sales of Onychomycosis by Therapies in USD MM (2017-2028)
Table 44: United States-Market Size of Onychomycosis in USD MM (2017-2028)
Table 45: United States-Market Share Onychomycosis by Therapies in USD MM (2017-2028)
Table 46: United States-Market Sales of Onychomycosis by Therapies in USD MM (2017-2028)
Table 47: Germany-Market Size of Onychomycosis in USD MM (2017-2028)
Table 48: Germany-Market Share Onychomycosis by Therapies in USD MM (2017-2028)
Table 49: Germany-Market Sales of Onychomycosis by Therapies in USD MM (2017-2028)
Table 50: France-Market Size of Onychomycosis in USD MM (2017-2028)
Table 51: France-Market Share Onychomycosis by Therapies in USD MM (2017-2028)
Table 52: France-Market Sales of Onychomycosis by Therapies in USD MM (2017-2028)
Table 53: Italy-Market Size of Onychomycosis in USD MM (2017-2028)
Table 54: Italy-Market Share Onychomycosis by Therapies in USD MM (2017-2028)
Table 55: Italy-Market Sales of Onychomycosis by Therapies in USD MM (2017-2028)
Table 56: Spain-Market Size of Onychomycosis in USD MM (2017-2028)
Table 57: Spain-Market Share Onychomycosis by Therapies in USD MM (2017-2028)
Table 58: Spain-Market Sales of Onychomycosis by Therapies in USD MM (2017-2028)
Table 59:UK-Market Size of Onychomycosis in USD MM (2017-2028)
Table 60:UK-Market Share Onychomycosis by Therapies in USD MM (2017-2028)
Table 61:UK-Market Sales of Onychomycosis by Therapies in USD MM (2017-2028)
Table 62: Japan-Market Size of Onychomycosis in USD MM (2017-2028)
Table 63: Japan-Market Share Onychomycosis by Therapies in USD MM (2017-2028)
Table 64: Japan-Market Sales of Onychomycosis by Therapies in USD MM (2017-2028)